The Y606C RET mutation causes a receptor gain of function

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Medullary thyroid carcinoma (MTC) is frequently associated with multiple endocrine neoplasia type 2A (MEN2A).
• Germline RET mutations are implicated in nearly all MEN2A cases, highlighting the RET proto-oncogene's critical role.

Observation:

• A specific activating germline RET point mutation, Y606C (cysteine substitution at tyrosine 606), was identified in a patient with MTC.
• This mutation was characterized in vitro using transfected NIH3T3 fibroblasts to assess its impact on RET signaling.

Findings:

• The Y606C mutation leads to increased RET receptor dimerization and constitutive activation, evidenced by elevated Y905 phosphorylation.
• Constitutively active RET signaling significantly increased ERK2 phosphorylation, indicating pathway dysregulation.

Implications:

• The Y606C RET mutation is pathogenetically relevant to MTC development.
• Understanding this mutation's role in RET activation provides insights into MTC pathogenesis.
• This discovery may inform future therapeutic strategies targeting RET-driven thyroid cancers.